Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases

Oncogene

Volumn 33, Issue 36, 2014, Pages 4485-4495

  Ueda, J ^a   Matsuda, Y ^a   Yamahatsu, K ^a   Uchida, E ^a   Naito, Z ^a   Korc, M ^b   Ishiwata, T ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EMT; ESRP1; FGFR 2 IIIb; FGFR 2 IIIc; pancreatic cancer

Indexed keywords

ESRP1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; ISOPROTEIN; RNA BINDING PROTEIN;

ALTERNATIVE RNA SPLICING; ANIMAL; ARTICLE; CELL MOTION; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER TUMOR; MALE; METABOLISM; METASTASIS; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RNA-BINDING PROTEINS;

EID: 84884666662     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.392     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Cho K, Ishiwata T, Uchida E, Nakazawa N, Korc M, Naito Z et al. Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. Am J Pathol 2007; 170: 1964-1974.
3. Ishiwata T, Friess H, Buchler MW, Lopez ME, Korc M. Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer. Am J Pathol 1998; 153: 213-222.
4. Dionne CA, Crumley G, Bellot F, Kaplow JM, Searfoss G, Ruta M et al. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J 1990; 9: 2685-2692.
5. Miki T, Fleming TP, Bottaro DP, Rubin JS, Ron D, Aaronson SA. Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science 1991; 251: 72-75.
6. Savagner P, Valles AM, Jouanneau J, Yamada KM, Thiery JP. Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelialmesenchymal transition in rat bladder carcinoma cells. Mol Biol Cell 1994; 5: 851-862.
7. Katoh M. FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. J Invest Dermatol 2009; 129: 1861-1867.
8. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008; 19: 294-308.
9. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993; 13: 4513-4522.
10. Ishiwata T, Matsuda Y, Yamamoto T, Uchida E, Korc M, Naito Z. Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol 2012; 180: 1928-1941.
11. Hovhannisyan RH, Carstens RP. Heterogeneous ribonucleoprotein m is a splicing regulatory protein that can enhance or silence splicing of alternatively spliced exons. J Biol Chem 2007; 282: 36265-36274.
12. Mauger DM, Lin C, Garcia-Blanco MA. hnRNP H.and hnRNP F complex with Fox2 to silence fibroblast growth factor receptor 2 exon IIIc. Mol Cell Biol 2008; 28: 5403-5419.
13. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009; 33: 591-601.
14. Warzecha CC, Shen S, Xing Y, Carstens RP. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol 2009; 6: 546-562.
15. Leontieva OV, Ionov Y. RNA-binding motif protein 35A is a novel tumor suppressor for colorectal cancer. Cell Cycle 2009; 8: 490-497.
16. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett 2011; 300: 66-78.
17. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68: 3645-3654.
18. Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 2011; 7: e1002218.
19. Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S et al. An ESRPregulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J 2010; 29: 3286-3300.
20. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142.
21. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008; 1: 306-316.
22. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218-1249.
23. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 2004; 57: 630-636.
24. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998; 7: 25-41.
25. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
26. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617.
27. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009; 9: 639-651.
28. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18: 4266-4276.
29. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
30. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
31. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
32. Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L et al. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proc Natl Acad Sci USA 2012; 109: 19280-19285.
33. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40: 1413-1415.
34. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-476.
35. Johnson M, Sharma M, Henderson BR. IQGAP1 regulation and roles in cancer. Cell Signal 2009; 21: 1471-1478.
36. Wickstrom SA, Lange A, Hess MW, Polleux J, Spatz JP, Kruger M et al. Integrinlinked kinase controls microtubule dynamics required for plasma membrane targeting of caveolae. Dev Cell 2010; 19: 574-588.
37. Bailey KM, Liu J. Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase. J Biol Chem 2008; 283: 13714-13724.
38. Yan L, Gu H, Li J, Xu M, Liu T, Shen Y et al. RKIP and 14-3-3epsilon exert an opposite effect on human gastric cancer cells SGC7901 by regulating the ERK/ MAPK pathway differently. Dig Dis Sci 2013; 58: 389-396.
39. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064-1074.
40. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148: 349-361.
41. Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 2012; 148: 21-23.
42. Kawase R, Ishiwata T, Matsuda Y, Onda M, Kudo M, Takeshita T et al. Expression of fibroblast growth factor receptor 2 IIIc in human uterine cervical intraepithelial neoplasia and cervical cancer. Int J Oncol 2010; 36: 331-340.
43. Matsuda Y, Yamamoto T, Kudo M, Kawahara K, Kawamoto M, Nakajima Y et al. Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma. Int J Oncol 2008; 33: 1177-1185.
44. Matsuda Y, Naito Z, Kawahara K, Nakazawa N, Korc M, Ishiwata T. Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Cancer Biol Ther 2011; 11: 512-523.
45. Gorg A, Obermaier C, Boguth G, Csordas A, Diaz JJ, Madjar JJ. Very alkaline immobilized pH gradients for two-dimensional electrophoresis of ribosomal and nuclear proteins. Electrophoresis 1997; 18: 328-337.
46. Gorg A, Obermaier C, Boguth G, Weiss W. Recent developments in two-dimensional gel electrophoresis with immobilized pH gradients: wide pH gradients up to pH 12, longer separation distances and simplified procedures. Electrophoresis 1999; 20: 712-717.
47. Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N, Nakamura M. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice. Int J Onco 2007; 31: 741-751.
48. Seiden-Long I, Navab R, Shih W, Li M, Chow J, Zhu CQ et al. Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis 2008; 29: 647-655.